dyslipidemia
DYSLIPIDEMIA
Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.

Definition

  • An abnormality in lipoprotein metabolism that results in elevations of low density lipoprotein-cholesterol(LDL-C), total cholesterol (TC), triglycerides (TG), and/or non-high-density lipoprotein-cholesterol (non-HDL-C) levels, or significantly reduced high-density lipoprotein-cholesterol (HDL-C) levels
  • Increase in serum concentration of TC, LDL, TG or non-HDL-C are equivalent to increased risk for cardiovascular diseases

Etiology

  • Depends on the type of dyslipidemia
  • Hereditary disorders associated with dyslipidemia include familial hypertriglyceridemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, chylomicronemia
  • Secondary causes include diabetes mellitus, diet, alcohol intake, hypothyroidism, renal failure, medications (glucocorticoids, beta-blockers, thiazides, estrogen therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, one year ago
Earlier age of menarche is significantly linked to a higher risk of gestational diabetes mellitus (GDM) independent of other risk factors, according to a recent study.
one year ago
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Elvira Manzano, one year ago
Hyperbaric oxygen therapy improves long-term survival in patients with chronic diabetic foot ulcers, according to 6-year follow-up data from the HODFU* study.
one year ago
This newsletter reports recent updates on diabetes management from the 18th ASEAN Federation of Endocrine Societies (AFES) Congress held in Kuala Lumpur, Malaysia, with a special highlight on the use of biosimilar insulins in managing diabetes.